Lino-Silva Leonardo S, Salcedo-Hernández Rosa A, García-Gómez Miguel A, Ruiz-García Erika B, Aguilar-Romero José M, Domínguez-Rodríguez Jorge A, Herrera-Gómez Ángel, Maldonado-Martínez Héctor A
Instituto Nacional de Cancerología, Mexico City, Mexico
Instituto Nacional de Cancerología, Mexico City, Mexico.
Int J Surg Pathol. 2016 Feb;24(1):24-8. doi: 10.1177/1066896915603121. Epub 2015 Aug 27.
The immunoreactivity of thyroid transcription factor-1 (TTF-1) is a very specific marker for lung and thyroid neoplasms; the expression of TTF-1 has also been demonstrated in extrapulmonary carcinomas. We examined the expression of TTF-1 in 15 intestinal-type adenocarcinomas of the extrahepatic bile duct. We then compared the expression to TTF-1 staining with other immunohistochemical markers including cytokeratin (CK) 7, CK20, caudal-type homeobox transcription factor 2 (CDX2), Napsin A, and MUC2. We additionally compared the clinicopathological prognostic factors with the TTF-1 expression status.
Nuclear TTF-1 staining was detected in 2 cases (13.3%), and Napsin A was positive in the same 2 cases (13.3%). All cases were positive for CK20, CDX2, and MUC2; 5 cases were positive for CK7. There was no correlation between TTF-1 expression and the clinicopathological characteristics.
To avoid potential pitfalls, TTF-1 should be interpreted in conjunction with the clinical setting, histology, and the results of markers such as CK7, CK20, Napsin A, and CDX2. This report is the first of TTF-1 positivity in adenocarcinomas from the extrahepatic biliary tract.
